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Pharmacological Magnetic Resonance Imaging (phMRI) is a variant of conventional MRI
that adds pharmacological manipulations in order to study the effects of drugs, or
uses pharmacological probes to investigate basic or applied (e.g., clinical) neuroscience
questions. Issues that may confound the interpretation of results from various types of
phMRI studies are briefly discussed, and a set of methodological strategies that can
mitigate these problems are described. These include strategies that can be employed
at every stage of investigation, from study design to interpretation of resulting data,
and additional techniques suited for use with clinical populations are also featured.
Pharmacological MRI is a challenging area of research that has both significant
advantages and formidable difficulties, however with due consideration and use of these
strategies many of the key obstacles can be overcome.
Keywords: pharmocological MRI, pharmaco fMRI, phMRI, methodology, neuroscience, cognitive neuroscience,
psychopharmacology, phfMRI
Introduction
Twenty-five years after its conception, functional MRI (fMRI) remains a stalwart technique in
cognitive neuroscience research. This well-established method of investigating “activation” of the
brain can also be combined with pharmacological agents; a technique (possibly contentiously;
Sauter and Rudin, 2000) referred to as pharmacological MRI or pharmaco-fMRI (phMRI). This
technique is of increasing interest in drug discovery (Wise and Tracey, 2006) and in the exploration
of neurological and mental disorder (Honey and Bullmore, 2004). The use of MRI to study
drug effects shares many challenges with standard fMRI (including issues of reliability and
reproducibility; Zuo and Xing, 2014; Zuo et al., 2014) but also presents other unique difficulties.
The purpose of this brief review is to outline some of the main considerations that need to be
addressed when designing and carrying out phMRI studies.
Broadly, phMRI studies can be classified on two dimensions (Figure 1A): the general aims of
the study, and the methods employed. In terms of the investigational aims, “challenge” studies
(Figure 1B) phMRI represents a potentially powerful tool in drug discovery, providing real time
neurophysiological data on drug action (Upadhyay et al., 2011) as part of early-phase clinical
trials, and more often uses healthy participants. The primary aim here is to investigate the
mechanism of drug action. In contrast, “activation” studies (Figure 1C) phMRI studies fall under
the general classification of experimental medicine. They are typically more hypothesis driven
(Iannetti and Wise, 2007; Carhart-Harris et al., 2014) and use established drugs, with known
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FIGURE 1 | Schematics representing different kinds of phMRI
studies. (A) The aims of phMRI (vertical axis) can be divided into
“challenge” studies aimed more at drug development (often using novel
compounds, and occurring in early-phase clinical trials, using healthy
volunteers), and “activation” studies that can be classed as experimental
medicine (more often using an established/marketed compound, and
may use clinical samples). Similarly the methods (horizontal axis) can be
divided into those focused on “standard” task-based fMRI, and those
using non-task methods (resting-state fMRI, ASL, or other MRI
contrasts). (B) A schematic of a typical “challenge” study focusing on
drug development. (C) A schematic of a typical “activation” or
experimental medicine study. NT, Neurotransmitter; fMRI, functional
Magnetic Resonance Imaging; BOLD, Blood Oxygen Level Dependent;
ASL, Arterial Spin Labeling.
mechanisms of action, in order to investigate neural systems
and probe individual symptoms and disorders, sometimes
using clinical populations. In terms of the methods used, a
broad distinction can be drawn between those studies that use
standard task-based fMRI, and others that use non-task methods
such as resting-state fMRI, Arterial Spin Labelling (ASL),
Magnetic Resonance Spectroscopy (MRS) or other methods. The
precise applicability of the issues and methodological techniques
outlined below to any particular study depends somewhat
on the quadrant that it occupies in Figure 1A (though some
may straddle multiple quadrants, for example it is relatively
common practice to include task and resting scans in a single
session). Previous reviews (e.g., Iannetti and Wise, 2007; Jenkins,
2012) have largely focused on drug discovery studies; however
important additional factors apply when conducting different
kinds of studies, particularly when using clinical samples.
Limitations in the Interpretation of Bold
Response
The most frequently used technique in fMRI studies involves
the measurement of changes in the Blood Oxygen Level
Dependent (BOLD) signal. BOLD is a naturally occurring
contrast representing local changes in the ratio of oxygenated
and deoxygenated hemoglobin (Buxton et al., 1998; Friston et al.,
2000). The BOLD response to a given stimulus is therefore a
proxy measure of neural activity and relies on a cascade of
cellular events; a relationship known as “neurovascular coupling”
(Logothetis et al., 2001). The use of BOLD as a measure of
underlying neural activity assumes that this cascade and its
relationship with the cerebral vasculature are intact. The BOLD
response is therefore dependent on baseline activity (from
which changes can be measured), intracellular pathways allowing
communication with the vasculature, and vascular responsivity.
Introducing a pharmacological agent to BOLD studies can
potentially disrupt this neurovascular coupling and in so doing,
render results more difficult to interpret (Iannetti and Wise,
2007). Drugs may disrupt local neuronal firing, the cellular
processes giving rise to the BOLD response, or modify baseline
neural or vascular activity across the entire brain, potentially
resulting in over/underestimations of effects (Hyder et al., 2002).
These considerations are particularly acute when using phMRI
in the development of novel agents, where drug effects on
neurovascular coupling are typically unknown, or when using
BOLD signal to infer activity at neurotransmitter receptors
(Breiter et al., 1997).
Many neurotransmitters are active in the systemic vasculature
and local neurovasculature, either directly, or by way of
modulating downstream signaling pathways (Jenkins, 2012). It
is therefore vital to take these factors into account in study
design. The remainder of this review highlights strategies that
can mitigate these confounding factors, and thereby bolster
the interpretation of phMRI investigations. Such “control”
conditions are discussed below and summarized in Figure 2.
Choice of Target Neurotransmitter and
Experimental Drug
The involvement of different neurotransmitters in systemic
processes varies. An early phMRI study of cocaine (Breiter et al.,
1997) highlighted the importance of vascular considerations
in the context of dopamine, which is vasoactive and plays an
important role in the control of systemic blood pressure (Amenta
et al., 2000; Tayebati et al., 2011). Dopamine has two families
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FIGURE 2 | Methodological considerations in phMRI studies
illustrated in a proposed timeline and considering both “challenge”
studies of novel agents and “activation” studies of established
agents deployed for the investigation of task paradigms and disease
states. NT, Neurotransmiter; PK, pharmacokinetic; ASL, Arterial Spin
Labelling; ROI, Region Of Interest.
of receptors; D1-like, and D2-like. Arterioles and capillaries
vasodilate upon activation of D1-like receptors, while capillary
activation of D2-like receptors results in vasoconstriction (Choi
et al., 2006). Alterations in BOLD signal may therefore reflect
positive haemodynamic changes coupled to agonism of D1-like
receptors or negative effects coupled to D2-like receptors (Chen
et al., 2005, 2010; Dixon et al., 2005; Choi et al., 2006, 2010; Shih
et al., 2009).
Another instructive example is caffeine, which effects alertness
and performance (e.g.,Wesensten et al., 2002; Brunye et al., 2012)
but is also a powerful cerebral vasoconstrictor (Mathew and
Wilson, 1985). The former results from antagonism of adenosine
A1 and A2A receptors, while the latter effect is due to selective
activity at A2A receptors (Diukova et al., 2012). Since the relative
density of these two receptor subtypes varies across the brain,
caffeine can have variable effects in different brain regions. Some
authors have shown that caffeine boosts the BOLD response
(Mulderink et al., 2002) while others show consistent reductions
(Diukova et al., 2012). Even for such a relatively selective and
widely-studied drug as caffeine, the situation is complex.
For non-selective drugs, in brain regions where there is a
preponderance of one receptor subtype there is likely to be a
relative excess of vasodilation/constriction. Potentially, in regions
where the two subtypes are equally abundant, no net change
might be observed.
Few drugs are selective for one receptor subtype or indeed
one neurotransmitter. With a single pharmacological agent it
is therefore possible to observe positive, negative, or no effects
on BOLD that may actually reflect more global vascular effects,
rather than task-related changes. Early consideration in phMRI
study design may help overcome these issues but more often
than not, additional control strategies are required to account
for these possibilities. These can be most effectively designed
with adequate physiological and pharmacokinetic data on the
neurotransmitter and drug of choice.
Matching Drug Effect to Regional Bold
Signal Change
Target neurotransmitters and receptor profiles are typically
understood at an early stage of drug development and this
can be used in combination with knowledge of brain receptor
distribution. Data on absorption rates and time to maximum
serum concentrations is available for clinical drugs, and is vital
in ascertaining the timing of administration. Additional data
should be sought on time to peak drug effect, onset, and duration
of action that will assist in establishing whether serial and
chronic administration is required, which may be used in a
challenge phMRI study, or single and one-off dosing, which
may be preferred in activation studies (Bloom et al., 1999). For
chronic administration, associating drug dose with the effect on
the BOLD response can further validate this approach. While
knowledge of the pharmacokinetics of drugs employed in phMRI
is a significant advantage, this is often unavailable for novel agents
in challenge phMRI studies and in these instances, phMRI may
itself be vital in obtaining this data.
Patient Group Heterogeneity
Research in patient groups requires additional considerations
to control for confounding factors that may weaken the
generalizability of the conclusions. Additional drugs may be co-
prescribed, necessitating multiple exclusion criteria and leading
to slow study recruitment. Although scientifically desirable, it
is not always possible, or indeed ethical, to ensure that patient
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groups are pharmacologically “pure.” In these instances it is vital
that co-prescribed medication is not in danger of independently
affecting the BOLD response, the task of interest, or of interacting
with the drug of interest. Variations in the illness state may
further affect the data acquired and illness severity may also vary
between subjects. These issues can be partly overcome through
the use of an additional “healthy” control group, enabling
modeling of drug effects and the identification of regions of
interest (ROI), if not already known, in a more homogeneous
and tightly-controlled group. Data from healthy subjects can be
important, but may not fully generalize to patient populations, as
the autoregulation of neurophysiology is such that chronic
responses to sustained alterations in neurotransmitters
and their receptors are potentially different to those in
health.
Monitoring and Correcting For Physiological
Parameters
Monitoring of physiological parameters in phMRI studies is
necessary in order to rule out systemic effects that may drive the
observed task-specific signal changes. This is a simple addition
to most studies, as physiological parameters (e.g., heart rate,
oxygen saturation) are routinely used for monitoring during
scanning. However, these data can also serve as an independent
source of noise that can be removed during analysis, and specific
methodology has been developed for this purpose (e.g., Glover
et al., 2000).
Using Separate Placebo Scans
Inferences about task-related BOLD signal changes are benefitted
greatly by comparison with signal during rest periods, but this
comparison remains under the experimental (drug) condition.
The use of a placebo scan, with the same paradigm deployed
in each session, may serve to strengthen inferences. Even
where single oral administration or intravenous infusion is
employed, the use of two scans (separated by days or weeks)
is preferable to a single scan session employing both placebo
and active drug (McKie et al., 2005; Deakin et al., 2008). This
is because the placebo would need to be administered first (in
order to ensure that observed effects do not reflect ongoing
drug effects during placebo administration), which introduces
an order effect. Separate scanning sessions are also able to
control for other variables (e.g., scanner thermal drift) that
may potentially confound the measurement of drug-related
effects. In the case of challenge phMRI studies, especially those
involving patient groups, this may be problematic, as it is
possible that physiological changes (e.g., disease progression)
have taken place between scans. This is also the case where
chronic administration of a drug is required, as the potential for
significant between-session variability in parameters that relate
to the participant and the scanning environment will also be
harder to control for. Nevertheless, the use of more than one
scanning session introduces the possibility of within and between
group/participant comparisons, which adds statistical power and
helps to additionally control for MRI-related factors affecting the
BOLD response.
Regions of Interest and Control Tasks
The use of a ROI approach (examining networks that have
already been established as responsive to a particular task or
sensory stimulus) can strengthen study design and in the context
of activation studies this approach is often feasible and preferable.
Although this increases the power to detect regional drug effects,
other effects detectable with a whole brain approach may be
missed. However, a ROI approach allows for the introduction
of an additional task, unrelated to the paradigm of interest, and
capable of activating unrelated networks. For example, a visual
task might be added to an activation study examining affective
changes (Murphy et al., 2009). The absence of any observable
effect on BOLD response to the visual task between the placebo
and drug scans suggests that drug effects on the main task of
interest cannot be accounted for by global vascular (or other)
effects. The power of this strategy to rule out extraneous factors as
an explanation for observed changes increases with the number
of control tasks employed (Pinel et al., 2007) but still cannot
completely rule out non-specific regional effects produced by the
primary task (Iannetti and Wise, 2007). A low threshold should
be set for the detection of drug effects on the control task in order
to avoid the underestimation of differences (Iannetti and Wise,
2007).
Subjective Responses
For drugs that involve measurable subjective effects, (e.g.,
drowsiness, alertness, other psychoactive effects), recording these
at predetermined time points during acquisition of scanning
data allows for the calculation of correlations between known
subjective effects of a drug and regional brain activation (Breiter
et al., 1997; Murphy and Mackay, 2011). Previous studies have
expanded on this concept using a regression approach to model
the time course of drug effects in the brain (Anderson et al., 2002).
Although elegant, this method assumes that these subjective
effects are entirely, or mostly, neuronal in origin. It is also a
method limited to drugs with known immediate psychological
effects, which may limit this approach to agents with more rapid
action.
Electrophysiological Recordings
A more optimal but perhaps less practical method of measuring
task and drug-related changes in neuronal activity is through
the use of electrophysiological measures, such as EEG and MEG.
These provide a direct measurement of neural activation with
excellent temporal resolution. EEG has poor spatial resolution
due to skull conductivity, whilst MEG has similar temporal
resolution to EEG but is better able to distinguish between
sources of activation (Murphy and Mackay, 2011). These
measures add additional data on task and drug-related activity,
recording different aspects of neuronal activity to the BOLD
signal. It is possible (though technically challenging) to record
BOLD and EEG data simultaneously; though MEG requires a
separate session. The decision to use EEG/MEG as an additional
source of “control” data may therefore be more dependent on the
nature of the stimulus or task employed than the presence of the
experimental drug condition (Iannetti and Wise, 2007).
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Vascular Controls
The ability to control for and measure vascular differences
between drug and placebo conditions is desirable in phMRI
studies in order to compensate for the limitations of the
interpretation of BOLD response to a drug challenge. These
methods also render additional drug and disease-related data that
may be independently desirable.
Assessing Baseline Perfusion
Arterial spin labeling (ASL) is a means of labeling arterial
bloodmagnetically, resulting in an additional naturally occurring
contrast medium (Williams et al., 1992). ASL can be used to
acquire estimations of baseline and dynamic changes in CBF.
This method involves a less favorable signal to noise ratio,
covers less brain volume and has worse temporal resolution than
BOLD measurements (Aguirre et al., 2002). However, it is more
sensitive to slower changes in CBF that are seen in response to
drug administration and may better localize neuronal activity
changes (Pfeuffer et al., 2002), as well as providing more directly
quantitative data than BOLD fMRI. Its advantage in phMRI is
in being able to assess changes in baseline perfusion that may
confound task-specific changes in BOLD signal (Cohen et al.,
2002; Bendlin et al., 2007). ASL data is increasingly thought of
as essential to phMRI study design (Iannetti and Wise, 2007;
Murphy and Mackay, 2011).
Assessing the Rate of Cerebral O2 Metabolism
and Vascular Reactivity
BOLD signal is a product of changes in CBF, CBV and the local
rate of O2 metabolism (CMRO2). The latter is an event that
occurs upstream of CBF and CBV responses and so provides
better spatial resolution in terms of assessing where changes in
neuronal activity occur than the composite measure of BOLD
signal alone (Bandettini and Wong, 1997). This can be achieved
experimentally by comparing BOLD response before and during
an experimentally-induced rise in CBF, achieved through the
inspiration of carbon dioxide (CO2) (Davis et al., 1998; Hoge
et al., 1999). The higher partial pressure of CO2 results in robust
cerebral vasodilation and increased perfusion without increases
in CMRO2 and so BOLD signal. In studies employing drug and
placebo scans, this paradigm can be deployed once during both
sessions (van der Zande et al., 2005; Pattinson et al., 2007).
Gene Polymorphism
Differences in the metabolism and degradation of
neurotransmitters may have a bearing on the activity
of drugs and drug effects. Enzymatic degradation of the
monoamines is a case in point; the activity of catecholamine-
O-methyltransferase (COMT) is one enzyme involved in this
process and is subject to genetic polymorphisms. Variations
in the val(158)met gene produce variations in COMT activity
and so variations in neurotransmitter activity (Mattay et al.,
2003). Such polymorphisms could influence drug effects on
task-specific activity but may also produce variations in the drug
effect on components of the BOLD response. An additional
“control” condition may therefore be employed through the
analysis of known polymorphisms for a given neurotransmitter
of interest. COMT val(158)met has been used in this regard in
both phMRI and positron emission tomography (PET) imaging
(Mattay et al., 2003; Zubieta et al., 2003). The use of gene
analysis also provides the potential for stratification of patient
groups so that more specific pharmacological targets can be
identified. phMRI therefore has applications in the growing field
of pharmacogenomics (Hariri and Weinberger, 2003; Wise and
Tracey, 2006; Bifone and Gozzi, 2011).
Functional Connectivity
One particular advantage of non-task based fMRI (i.e., resting-
state fMRI) is it enables analysis of functional connectivity
(Murphy and Mackay, 2011). The benefit here is that estimates
of functional connectivity rely more upon the degree to which
activity in different brain areas correlate, rather than the simple
amplitude of activity in any one region. As such, connectivity
measures may be less vulnerable to global drug effects than BOLD
signal changes used in conventional analyses. There are a great
number of methodological approaches to the analysis of resting-
state fMRI data (Cole et al., 2010) and many have been shown to
be sensitive markers of disease states and drug effects. However,
the precise functional nature of resting-state brain networks is
unresolved and this combined with the data-driven nature of
many analysis strategies impedes robust interpretations.
Conclusion/Summary
phMRI continues to be a novel, informative, and important
method in drug discovery and basic/clinical neuroscience. It is
not without its shortfalls, but with appropriate considerations
in methodology and study design it has the potential to fill the
gap between MRI and PET methodologies on the frontier of
neuroscientific and pharmacological research.
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